EP1337656A1 - In vitro generation of recombinant adenovirus vectors - Google Patents

In vitro generation of recombinant adenovirus vectors

Info

Publication number
EP1337656A1
EP1337656A1 EP01980719A EP01980719A EP1337656A1 EP 1337656 A1 EP1337656 A1 EP 1337656A1 EP 01980719 A EP01980719 A EP 01980719A EP 01980719 A EP01980719 A EP 01980719A EP 1337656 A1 EP1337656 A1 EP 1337656A1
Authority
EP
European Patent Office
Prior art keywords
component
donor
expression
recombination
adenoviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01980719A
Other languages
German (de)
French (fr)
Inventor
Johann Winkler
Kenneth Robert Bundell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0027501.6A external-priority patent/GB0027501D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1337656A1 publication Critical patent/EP1337656A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Definitions

  • Adenoviruses are a group of DNA viruses which can cause generally mild infections in humans respiratory illness, conjunctivitis and infantile gastroenteritis. Almost grown in cell culture, adenoviruses have been widely studied for many years (e.g. RNA splicing was first described in adenovirus infected cell). The ability of adenoviruses to infect human cells at up to 100% efficiency has led to its use as a vector for introducing foreign (recombinant) DNA in both cell culture and in humans (gene therapy). Recombinant adenoviruses generally have certain regions of DNA deleted (e.g. El region necessary for replication, E3 required for evading host immunity). The purpose of this is twofold.
  • the removal of non-necessary regions of DNA allows space for the introduction of foreign DNA which can then be packaged as adenovirus DNA and subsequently introduced into human cells (there is also some leeway for insertion of extra DNA into the genome without affecting infectivity).
  • the removal of the El region determines that the recombinant virus can infect human cells but not replicate; this is an important safety consideration.
  • DNA is transfected into a cell line (e.g. HEK 293) which has the El region engineered into its genome i.e. the cell line provides the replicative machinery lacking in the recombinant adenovirus.
  • Recombinant adenovirus technology is often based around human adenovirus type 5.
  • the genome for Ad5 is 35.935 kb. This whole sequence can be cloned into a plasmid vector and replicated in E.coli. However, because of the length of adenovirus sequence, there are very few suitable restriction enzyme sites available which would allow direct cloning into such a vector. To circumvent this problem, a two vector approach has been adopted. One vector contains the complete adenovirus sequence minus El and E3 sequence. The second vector contains a eukaryotic promoter (e.g.
  • CMN CMN upstream of a cloning site (for insertion of foreign D ⁇ A), and polyadenylation sequences necessary for stability of transcribed R ⁇ A. Flanking this expression cassette are two regions of adenovirus D ⁇ A which are common with adenovirus sequences in the first vector.
  • the expression cassette from the second vector can be introduced into the adenovirus sequence in the first vector by a process of homologous recombination. This tedious, exacting and time-consuming process has traditionally been performed in HEK 293 cells. Viruses produced have to be plaque purified, propagated and tested to ensure that the desired recombinant D ⁇ A has been introduced.
  • Recombinant adenoviral DNA can then be identified by restriction digest and clonal adenoviral DNA prepared in E.coli.
  • the clonal adenoviral DNA can then be transfected into HEK 293 cells and adenovirus produced thus effectively removing the need for plaque purification.
  • This method has now been commercialised (Q-biogene: AdeasyTM).
  • AdeasyTM Q-biogene
  • a further improvement with this system is that the recombinant adenovirus co-expresses green fluorescent protein from a second CMV promoter. This makes infection efficiency (and therefore gene delivery efficiency) simple to assess.
  • Our experience with the AdeasyTM system has shown that there can be difficulties with the recombination procedure.
  • a two component system for in vitro cloning of a heterologous polynucleotide into adenoviral DNA comprising: i) a first component which is an insert donor comprising a heterologous polynucleotide encoding a heterologous polypeptide; and ii) a second component which is a vector donor comprising an adenovirus genome and an expression cassette; wherein the insert donor and vector donor are adapted for site specific recombination for insertion of the heterologous polynucleotide into the expression cassette capable of forming an adenoviral expression clone in vitro in the presence of a suitable recombination mediator protein or proteins.
  • the site specific recombination uses recombination sites from phage lambda.
  • recombination sites from phage lambda.
  • the reader is referred to the following: Landy (1989) Ann Rev Biochem 58, 913; and Ptashne (1992) A Genetic Switch, Cell Press, Cambridge.
  • the reader is also referrred to US 5888732 (Life Technologies) for further technical details of site specific recombination using insert donor and vector donor moieties.
  • the recombination reactions produce highly specific cutting and ligation reactions such that the recombination mediator proteins cut to the left and right of the heterologous polynucleotide in the insert donor and ligate it into the vector donor whereby to form an adenoviral expression clone.
  • the expression cassette comprises a polynucleotide encoding a fluorescent protein downstream of an internal ribosome entry site for expression from the same mRNA as the heterologous polypeptide.
  • system described herein comprises at least one of the following:
  • a vector donor comprising a ccdB gene
  • an insert donor comprising a selectable marker
  • the system comprises all of the elements i) to vi).
  • the attB x attP reaction is mediated by proteins it and HF (Clonase BPTM, Life Technologies).
  • the attL x attR reaction is mediated by proteins L t, IHF, and Xis (Clonase LRTM, Life Technologies). Lit and Xis are from lambda; IHF is from E. coli.
  • "x" represents recombination.
  • Engineered recombination sites offereing efficiency or specificity advantages over wild type sequences as described in US 5888732 are also contemplated.
  • the method uses first and second components as defined in elements i) to vi) above, the host organism for expression clone replication is E. coli and the host organism for adenoviral replication is HEK 293 cells.
  • Figure 3 shows in vitro cloning of lac Z into an adenoviral expression clone
  • E Lit, IHF, Xis proteins.
  • F Will not grow on ampicillin or in E.coli DH5 ⁇ (ccdB lethal).
  • G Transform E.coli (eg. DH5 ⁇ ) and select on ampicillin plates identify correct clones and transfect HEK 293 cells to generate virus.
  • a vector which contains: the complete adenovirus genome (minus El and E3); an expression cassette comprising: CMN promoter, attRl - Chloramphenicol resistance -ccdB -attR2, internal ribosome entry site (IRES), fluorescent protein sequence, and SN40 polyadenylation sequence.
  • This vector is a vector donor. Any sequence in an insert donor can be efficiently cloned directly into this vector donor via in vitro recombination. Background is reduced to zero due to the ccdB gene toxicity in E.coli (the vector donor D ⁇ A is propagated in E.coli strain DB3.1 which has a gyrA mutation and tolerates ccdB). Thus in vitro recombination of the gene of interest in an insert donor into the vector donor followed by transformation in E.coli DH5a using selection for the vector donor (vector donor ampicillin resistant, insert donor kanamycin resistant) should only result in recombinant adenoviral D ⁇ A since the ccdB gene is toxic.
  • the D ⁇ A is then digested to remove the plasmid backbone and directly transfected into HEK 293 cells to generate recombinant virus.
  • This system to generate recombinant expressing lacZ from an insert donor containing lacZ. It is quick and efficient and we believe has a considerable advantage over the current AdEasy system.
  • these constructs express a fluorescent protein from an IRES element. This means that they are expressed from the same transcribed messenger R ⁇ A as the recombinant gene. With 'AdEasyTM', the green fluorescent protein is expressed from a second separate CMN promoter. Li this case expression of the fluorescent protein is no guarantee of recombinant gene transcription.
  • a 3168 base pair fragment comprising the entire coding region of the E.coli lacZ gene preceded by a sequence encoding six histidine residues was isolated from pZeoSN2/lacZ (Livitrogen) by restriction enzyme digest ( ⁇ co I and EcoR I).
  • the lacZ D ⁇ A fragment was separated from the plasmid backbone by gel electrophoresis, excised from the gel and purified using GenecleanTM Spin Kit. The isolated fragment was then cloned into the ⁇ co I and EcoR I sites of insert donor pE ⁇ TR 11 (Life Technologies). Briefly, pE ⁇ TR 11 was digested with ⁇ co I and EcoR I, purified by gel excision and dephosphorylated with shrimp alkaline phosphatase (Roche).
  • the lac Z fragment was then ligated to the pENTR 11 plasmid in vitro using T4 DNA ligase (Roche) and transformed into E.coli DH10B electrocompetent cells (Life Technologies). Following overnight growth on kanamycin plates, a pENTR 11 clone containing lacZ was identified by restriction digest of plasmid DNA. Thus this clone contained the lacZ coding sequence flanked by 1 bacteriophage attLl and attL2 sites.
  • vector donor comprising the following was prepared:
  • This vector donor was incubated together with insert donor (pE ⁇ TR 11 / lacZ) in a buffer containing recombination mediator proteins Lit, HF, and Xis (LR clonaseTM, Life
  • the resultant D ⁇ A was transformed into E.coli DH10B electrocompetent cells and plated out on ampicillin plates. 15 colonies were selected from the several thousand present and analysed by restriction digest of prepared plasmid D ⁇ A. Of these, 14
  • adenoviral lacZ plasmid D ⁇ A was digested with Pac I to remove the plasmid backbone and transfected into HEK 293 cells using LipofectamineTM (Life Technologies). After 12 days incubation, viral growth was apparent and virus was harvested from cells lysates.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides a two component system for in vitro cloning of a heterologous polynucleotide into adenoviral DNA. The first component is an insert donor comprising a heterologous polynucleotide encoding a heterologous polypeptide. The second component is a vector donor comprising an adenovirus genome and an expression cassette. The insert donor and vector donor are adapted for site specific recombination using recombination sites from phage lambda for insertion of the heterologous polynucleotide into the expression cassette capable of forming an adenoviral expression clone in vitro in the presence of a suitable recombination mediator protein or proteins. The invention also provides a method of making recombinant adenovirus and use of the first and second components in such a method.

Description

VECTOR
Adenoviruses are a group of DNA viruses which can cause generally mild infections in humans respiratory illness, conjunctivitis and infantile gastroenteritis. Easily grown in cell culture, adenoviruses have been widely studied for many years (e.g. RNA splicing was first described in adenovirus infected cell). The ability of adenoviruses to infect human cells at up to 100% efficiency has led to its use as a vector for introducing foreign (recombinant) DNA in both cell culture and in humans (gene therapy). Recombinant adenoviruses generally have certain regions of DNA deleted (e.g. El region necessary for replication, E3 required for evading host immunity). The purpose of this is twofold. First, the removal of non-necessary regions of DNA allows space for the introduction of foreign DNA which can then be packaged as adenovirus DNA and subsequently introduced into human cells (there is also some leeway for insertion of extra DNA into the genome without affecting infectivity). Second, the removal of the El region determines that the recombinant virus can infect human cells but not replicate; this is an important safety consideration. To generate and replicate recombinant adenovirus, DNA is transfected into a cell line (e.g. HEK 293) which has the El region engineered into its genome i.e. the cell line provides the replicative machinery lacking in the recombinant adenovirus.
Recombinant adenovirus technology is often based around human adenovirus type 5. The genome for Ad5 is 35.935 kb. This whole sequence can be cloned into a plasmid vector and replicated in E.coli. However, because of the length of adenovirus sequence, there are very few suitable restriction enzyme sites available which would allow direct cloning into such a vector. To circumvent this problem, a two vector approach has been adopted. One vector contains the complete adenovirus sequence minus El and E3 sequence. The second vector contains a eukaryotic promoter (e.g. CMN) upstream of a cloning site (for insertion of foreign DΝA), and polyadenylation sequences necessary for stability of transcribed RΝA. Flanking this expression cassette are two regions of adenovirus DΝA which are common with adenovirus sequences in the first vector. Thus, the expression cassette from the second vector can be introduced into the adenovirus sequence in the first vector by a process of homologous recombination. This tedious, exacting and time-consuming process has traditionally been performed in HEK 293 cells. Viruses produced have to be plaque purified, propagated and tested to ensure that the desired recombinant DΝA has been introduced. A recent advance in recombinant adenovirus generation, the 'AdEasy™' system (He, T-G et al, PNAS, 95, 1998, 2509 - 2514), simplifies the procedure by carrying out the plasmid recombination step in E.coli strain BJ 5183 which allows limited recombination.
Recombinant adenoviral DNA can then be identified by restriction digest and clonal adenoviral DNA prepared in E.coli. The clonal adenoviral DNA can then be transfected into HEK 293 cells and adenovirus produced thus effectively removing the need for plaque purification. This method has now been commercialised (Q-biogene: Adeasy™). A further improvement with this system is that the recombinant adenovirus co-expresses green fluorescent protein from a second CMV promoter. This makes infection efficiency (and therefore gene delivery efficiency) simple to assess. Our experience with the Adeasy™ system has shown that there can be difficulties with the recombination procedure. This can involve high background from the expression vector, unpredictable recombination events and low recombination efficiency. Thus there is a need for further improvements in recombinant adenovirus generation. According to one aspect of the present invention there is provided a two component system for in vitro cloning of a heterologous polynucleotide into adenoviral DNA comprising: i) a first component which is an insert donor comprising a heterologous polynucleotide encoding a heterologous polypeptide; and ii) a second component which is a vector donor comprising an adenovirus genome and an expression cassette; wherein the insert donor and vector donor are adapted for site specific recombination for insertion of the heterologous polynucleotide into the expression cassette capable of forming an adenoviral expression clone in vitro in the presence of a suitable recombination mediator protein or proteins. Preferably the site specific recombination uses recombination sites from phage lambda. For a review of recombination in lambda the reader is referred to the following: Landy (1989) Ann Rev Biochem 58, 913; and Ptashne (1992) A Genetic Switch, Cell Press, Cambridge. The reader is also referrred to US 5888732 (Life Technologies) for further technical details of site specific recombination using insert donor and vector donor moieties. In use, the recombination reactions produce highly specific cutting and ligation reactions such that the recombination mediator proteins cut to the left and right of the heterologous polynucleotide in the insert donor and ligate it into the vector donor whereby to form an adenoviral expression clone. Preferably the expression cassette comprises a polynucleotide encoding a fluorescent protein downstream of an internal ribosome entry site for expression from the same mRNA as the heterologous polypeptide.
Preferably system described herein comprises at least one of the following:
i) a CMV promoter in the expression cassette;
ii) an adenovirus type 5 genome that is replication deficient;
iii) a vector donor comprising a ccdB gene;
iv) an insert donor comprising a selectable marker;
v) a vector donor comprising a selectable marker; and
vi) site specific recombination sites based on either phage lambda attB with attP or attL with attR.
More preferably the system comprises all of the elements i) to vi). The attB x attP reaction is mediated by proteins it and HF (Clonase BP™, Life Technologies). The attL x attR reaction is mediated by proteins L t, IHF, and Xis (Clonase LR™, Life Technologies). Lit and Xis are from lambda; IHF is from E. coli. Here "x" represents recombination.
Engineered recombination sites offereing efficiency or specificity advantages over wild type sequences as described in US 5888732 are also contemplated.
According to another aspect of the invention there is provided a method of making recombinant adenovirus comprising:
i) mixing in vitro a first component as defined herein with a second component as defined herein in the presence of a suitable recombination mediator protein or proteins so as to form an expression clone;
ii) transformation of product from i) in to a host organism suitable for expression clone replication; and
iii) transfection of product from ii) in to a host suitable for adenoviral replication. Preferably the method uses first and second components as defined in elements i) to vi) above, the host organism for expression clone replication is E. coli and the host organism for adenoviral replication is HEK 293 cells.
According to another aspect of the invention there is provided a second component as defined herein.
According to another aspect of the invention there is provided use of a first component as defined herein in a method as defined herein.
According to another aspect of the invention there is provided the use of a second component as defined herein in a method as defined herein.
The invention is illustrated below by the following non-limiting Example in which: Figure 1 shows a Nector Donor wherein 1 = fluorescent protein, 2= IRES element, 3= attR2, 4= ccdB + cmR, 5= attRl, 6= adenovirus sequence (ΔE1/ΔE3), 7= origin of replication, 8= ampicillin resistance, 9= restriction enzyme sites for excision of plasmid backbone, 10= adenovirus LITR sequence, and 11= SN40 PA;
Figure 2 shows an Insert Donor in which 1= gene of interest, 2= attL2, 3= kanamycin resistance, 4= origin of replication, 5= attLl.
Figure 3 shows in vitro cloning of lac Z into an adenoviral expression clone wherein A= Insert Donor wherein 1= gene of interest (lacZ), 2= attL2, 3= Knr, 4= ori, 5= attLl. B = Nector Donor wherein 1= fluorescent protein, 2= LRES, 3= attR2, 4= ccdB, 5= attRl, 6= CMN promoter, 7= adenovirus sequence, 8= ori, 9= Ampr, 10= SN40 PA. C= Expression clone (Ampr) wherein 1= fluorescent protein, 2= IRES, 3= AttB2, 4= lacZ, 5= AttBl, 6= CMN promoter, 7= adenovirus sequence, 8= ori, 9= Amp2, 10= SN40 PA. D= Bi-product (kanar) wherein 1= ccdB, 2= AttP2, 3= Knr, 4= ori, 5= AttPl. E= Lit, IHF, Xis proteins.
F= Will not grow on ampicillin or in E.coli DH5α (ccdB lethal).
G= Transform E.coli (eg. DH5α) and select on ampicillin plates identify correct clones and transfect HEK 293 cells to generate virus.
General molecular biology techniques are described in "Current Protocols in Molecular Biology Volumes 1-3 , edited by F M Asubel, R Brent and R E Kingston; published by John Wiley, 1998. Example 1
We have used an in vitro cloning system to make recombinant adenovirus generation simpler and more efficient. Also we have incorporated fluorescent protein as infection marker (Matz et al (1999) Nat. Biotechnol. 17, 969-973; Lukyanov et al (2000) J. Biol. Chem. 275, 25879-25882).
Li brief, we have created a vector which contains: the complete adenovirus genome (minus El and E3); an expression cassette comprising: CMN promoter, attRl - Chloramphenicol resistance -ccdB -attR2, internal ribosome entry site (IRES), fluorescent protein sequence, and SN40 polyadenylation sequence.
This vector is a vector donor. Any sequence in an insert donor can be efficiently cloned directly into this vector donor via in vitro recombination. Background is reduced to zero due to the ccdB gene toxicity in E.coli (the vector donor DΝA is propagated in E.coli strain DB3.1 which has a gyrA mutation and tolerates ccdB). Thus in vitro recombination of the gene of interest in an insert donor into the vector donor followed by transformation in E.coli DH5a using selection for the vector donor (vector donor ampicillin resistant, insert donor kanamycin resistant) should only result in recombinant adenoviral DΝA since the ccdB gene is toxic. The DΝA is then digested to remove the plasmid backbone and directly transfected into HEK 293 cells to generate recombinant virus. We have used this system to generate recombinant expressing lacZ from an insert donor containing lacZ. It is quick and efficient and we believe has a considerable advantage over the current AdEasy system. Also, these constructs express a fluorescent protein from an IRES element. This means that they are expressed from the same transcribed messenger RΝA as the recombinant gene. With 'AdEasy™', the green fluorescent protein is expressed from a second separate CMN promoter. Li this case expression of the fluorescent protein is no guarantee of recombinant gene transcription.
A 3168 base pair fragment comprising the entire coding region of the E.coli lacZ gene preceded by a sequence encoding six histidine residues was isolated from pZeoSN2/lacZ (Livitrogen) by restriction enzyme digest (Νco I and EcoR I). The lacZ DΝA fragment was separated from the plasmid backbone by gel electrophoresis, excised from the gel and purified using Geneclean™ Spin Kit. The isolated fragment was then cloned into the Νco I and EcoR I sites of insert donor pEΝTR 11 (Life Technologies). Briefly, pEΝTR 11 was digested with Νco I and EcoR I, purified by gel excision and dephosphorylated with shrimp alkaline phosphatase (Roche). The lac Z fragment was then ligated to the pENTR 11 plasmid in vitro using T4 DNA ligase (Roche) and transformed into E.coli DH10B electrocompetent cells (Life Technologies). Following overnight growth on kanamycin plates, a pENTR 11 clone containing lacZ was identified by restriction digest of plasmid DNA. Thus this clone contained the lacZ coding sequence flanked by 1 bacteriophage attLl and attL2 sites.
For generation of adenoviral DNA containing the lacZ gene, vector donor comprising the following was prepared:
(i) Adenovirus DNA sequence (minus El and E3 regions)
(ii) Exciseable plasmid backbone (ampicillin resistant) (iii) CMN promoter for expression of heterologous genes in mammalian cells
(iv) chloramphenicol resistance gene and E.coli ccdB gene flanked by 1 bacteriophage attRl and attR2 sites
(v) an internal ribosome entry site (IRES) element
(vi) fluorescent protein coding sequences (vii) SN40 polyadenylation sequence for mRΝA stability.
This vector donor was incubated together with insert donor (pEΝTR 11 / lacZ) in a buffer containing recombination mediator proteins Lit, HF, and Xis (LR clonase™, Life
Technologies). The resultant DΝA was transformed into E.coli DH10B electrocompetent cells and plated out on ampicillin plates. 15 colonies were selected from the several thousand present and analysed by restriction digest of prepared plasmid DΝA. Of these, 14
(93 %) contained the desired adenoviral lacZ construct and only 1 was not the desired construct.
For generation of adenoviruses expressing lacZ and fluorescent protein, adenoviral lacZ plasmid DΝA was digested with Pac I to remove the plasmid backbone and transfected into HEK 293 cells using Lipofectamine™ (Life Technologies). After 12 days incubation, viral growth was apparent and virus was harvested from cells lysates.
Comparative Example 1 Recombinant adenoviral DΝA generation using "AdEasy™" homologous recombination in E.coli BJ 5183 was much less productive and efficient than the in vitro method of Example 1. Li general, far fewer colonies were obtained (<20 per transfection compared with many thousands) and of these fewer were the desired recombinant (typically 10 - 30%).

Claims

Claims
1 A two component system for in vitro cloning of a heterologous polynucleotide into adenoviral DNA comprising:
i) a first component which is an insert donor comprising a heterologous polynucleotide encoding a heterologous polypeptide; and
ii) a second component which is a vector donor comprising an adenovirus genome and an expression cassette;
wherein the insert donor and vector donor are adapted for site specific recombination for insertion of the heterologous polynucleotide into the expression cassette capable of forming an adenoviral expression clone in vitro in the presence of a suitable recombination mediator protein or proteins.
2 A system according to claim 1 wherein the site specific recombination uses recombination sites from phage lambda.
3. A system according to any previous claim in which the expression cassette comprises a polynucleotide encoding a fluorescent protein downstream of an internal ribosome entry site for expression from the same mRNA as the heterologous polypeptide.
4. A system according to any previous claim comprising at least one of the following:
i) a CMN promoter in the expression cassette;
ii) an adenovirus type 5 genome that is replication deficient;
iii) a vector donor comprising a ccdB gene;
iv) an insert donor comprising a selectable marker;
v) a vector donor comprising a selectable marker; and
vi) site specific recombination sites based on either phage lambda attB with attP or attL with attR.
5. A system according to claim 4 comprising all of the claimed elements i) to vi).
6. A method of making recombinant adenovirus comprising:
i) mixing in vitro a first component as defined in any one of claims 1-5 with a second component as defined in any one of claims 1-5 in the presence of a suitable recombination mediator protein or proteins so as to form an expression clone;
ii) transformation of product from i) in to a host organism suitable for expression clone replication; and
iii) transfection of product from ii) in to a host suitable for adenoviral replication.
7 A method according to claim 6 in which the first and second components are as defined in claim 5, the host organism for expression clone replication is E. coli and the host organism for adenoviral replication is HEK 293 cells.
8 A second component as defined in any one of claims 1-5.
9. Use of a first component as defined in any one of claims 1-5 in a method as defined in claim 6 or 7.
10. Use of a second component as defined in any one of claims 1-5 in a method as defined in claim 6 or 7.
EP01980719A 2000-11-10 2001-11-06 In vitro generation of recombinant adenovirus vectors Withdrawn EP1337656A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0027501 2000-11-10
GBGB0027501.6A GB0027501D0 (en) 2000-11-10 2000-11-10 Vector
US25292700P 2000-11-27 2000-11-27
US252927P 2000-11-27
PCT/GB2001/004916 WO2002038783A1 (en) 2000-11-10 2001-11-06 Vector

Publications (1)

Publication Number Publication Date
EP1337656A1 true EP1337656A1 (en) 2003-08-27

Family

ID=26245268

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01980719A Withdrawn EP1337656A1 (en) 2000-11-10 2001-11-06 In vitro generation of recombinant adenovirus vectors

Country Status (4)

Country Link
EP (1) EP1337656A1 (en)
JP (1) JP2004513638A (en)
AU (1) AU2002212507A1 (en)
WO (1) WO2002038783A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2727689A1 (en) * 1994-12-01 1996-06-07 Transgene Sa NEW PROCESS FOR THE PREPARATION OF A VIRAL VECTOR
EP2322614A1 (en) * 1995-06-07 2011-05-18 Life Technologies Corporation Recombinational cloning using engineered recombination sites
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
CA2366914C (en) * 1999-03-05 2010-05-11 Merck & Co., Inc. Enhanced system for construction of adenovirus vectors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0238783A1 *

Also Published As

Publication number Publication date
JP2004513638A (en) 2004-05-13
AU2002212507A1 (en) 2002-05-21
WO2002038783A1 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
US10167478B2 (en) Replicative minicircle vectors with improved expression
US5922576A (en) Simplified system for generating recombinant adenoviruses
Dougherty et al. High mutation rate of a spleen necrosis virus-based retrovirus vector
US10167485B2 (en) Production of viral vectors
Carninci et al. Balanced-size and long-size cloning of full-length, cap-trapped cDNAs into vectors of the novel λ-FLC family allows enhanced gene discovery rate and functional analysis
JP2010193896A (en) Method for producing recombinant virus using site-specific recombination
CN113957089B (en) Vector system for screening regulatory sequences and application thereof
CN107475298A (en) CdtB gene overexpressions slow virus carrier and its construction method and the slow virus comprising cdtB genes and its application
CN107245493B (en) Vector for expressing aptamer ribozyme modified sgRNA regulated and controlled by theophylline and application
CN106520829A (en) Method for terminating biallelic gene transcription
CN108841866B (en) Adenovirus vector and construction method thereof
CN104928292A (en) Design method of sgRNA and lentivirus carrier formed by sgRNA and plasmids
US20040048381A1 (en) Vector
EP1337656A1 (en) In vitro generation of recombinant adenovirus vectors
EP1366177A1 (en) Cloning vectors and method for molecular cloning
CN116286904B (en) Bovine-derived CRISPR/boCas13a gene editing system, method and application
JP7407099B2 (en) Means to generate adenoviral vectors for cloning large nucleic acids
CN116875581A (en) Method for improving gene knock-in efficiency and accuracy by using Cpf1 non-retention end
CN116751763A (en) A Cpf1 protein, V-type gene editing system and its application
EP1012314A1 (en) A vector and method for preparation of dna libraries
CN107119018A (en) A kind of anti-apoptotic cell line and its method for building up and application
CN116790597A (en) sgRNA targeting TOR1A protein and application thereof
Long et al. Construction of a multi-functional helper-dependent adenovirus based system for cancer gene therapy
CN106868047B (en) A kind of recombinant adenovirus vector and its construction method and use
CN116064537A (en) A plant circRNA expression framework and its application

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030610

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20040917

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050330